Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant TACE + lenvatinib + cadonilimab for resectable hepatocellular carcinoma
ChiCTR2500113040Phase 2Completed
- Sponsor
- Fujian Provincial Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and cadonilimab in hepatocellular carcinoma (HCC), sponsored by Fujian Provincial Hospital. Primary endpoints: Major pathological response rate, Surgical mortality rate and 3 more. Started Nov 2025; status: completed.
02
Drugs
lenvatinibcadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500113040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113040.